2,750 results on '"Dummer, R"'
Search Results
2. The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective
3. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial
4. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
5. Predictors of responses to immune checkpoint blockade in advanced melanoma.
6. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
7. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
8. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
9. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆
10. Atypical spitzoid lesions: A molecular and histological analysis of two NTRK driven cases
11. Real-world outcomes for advanced melanoma in the adjuvant and unresectable setting: Single-center registry analysis
12. Integrated transcriptomics reveals cellular and molecular interactions in pruritic cutaneous T-cell lymphoma
13. Ipilimumab and nivolumab in uveal melanoma: report on toxicity and treatment intensity
14. 33P Impact of prior treatment on baseline immune biomarkers and nivolumab + relatlimab (NIVO+RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with melanoma from RELATIVITY-020
15. 118O Definitive results for NSCLC and bladder cancer cohorts in the phase IIa trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial)
16. Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial
17. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
18. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
19. LB1643 Novel insights into vitiligo-like depigmentation under immune checkpoint inhibitors in melanoma compared to classical vitiligo and healthy skin biopsies
20. Histiozytäre Neoplasien im Kontext der aktuellen Klassifikation
21. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
22. 1607 Multiomic analysis of immune-related adverse events (irAEs) in melanoma patients treated with anti-PD1-based immune checkpoint inhibitors (ICIs)
23. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
24. Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
25. A-317 - Real-world outcomes for advanced melanoma in the adjuvant and unresectable setting: Single-center registry analysis
26. A-113 - Integrated transcriptomics reveals cellular and molecular interactions in pruritic cutaneous T-cell lymphoma
27. Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1‐based immune checkpoint inhibitors
28. Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1 ‐based immune checkpoint inhibitors
29. Identifying the potential origin of mucin in primary cutaneous mucinoses—A retrospective study and analysis using histopathology and multiplex fluorescence staining
30. Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors
31. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023
32. The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres
33. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors
34. Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: rechallenge?
35. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
36. A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis
37. 243P Skin biopsies for pharmacodynamic studies of tebentafusp: A novel bispecific molecule against the melanocytic antigen gp100
38. PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
39. Survie à long terme chez les patients avec un mélanome avancé traités par NIVO et IPI dans l’étude CheckMate 067
40. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab
41. Sox2 is dispensable for primary melanoma and metastasis formation
42. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
43. Ausgewählte Publikationen
44. Patientenbetreuung
45. 1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma.
46. ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma
47. High-Throughput Screening Identifies Novel ROS-Inducing Small Molecules as a Therapy for Treatment-Resistant Melanoma
48. Vertical inhibition of the MAPK pathway as potential treatment strategy in NRAS-mutant melanoma
49. ROS induction as a strategy to target persister cancer cell metabolism
50. LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.